Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H13NO2.ClH |
| Molecular Weight | 215.677 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NCC(CC(O)=O)C1=CC=CC=C1
InChI
InChIKey=XSYRYMGYPBGOPS-UHFFFAOYSA-N
InChI=1S/C10H13NO2.ClH/c11-7-9(6-10(12)13)8-4-2-1-3-5-8;/h1-5,9H,6-7,11H2,(H,12,13);1H
| Molecular Formula | C10H13NO2 |
| Molecular Weight | 179.2157 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Phenibut (beta-phenyl-gamma-aminobutyric acid or 4-amino-3-phenylbutyric acid) is a neuropsychotropic drug that was discovered and introduced into clinical practice in Russia in the 1960s. It has anxiolytic and nootropic (cognition enhancing) effects. It acts as a GABA-mimetic, primarily at GABA(B) receptors. Pharmacological activity of racemic phenibut relies on R-phenibut and this correlates to the binding affinity of enantiomers of phenibut to the GABAB receptor. In addition R-phenibut binds to the α2-δ subunit of voltage-dependent calcium channels. It is highly effective in treating anxiety, post-traumatic stress disorder, depression, asthenia, insomnia, alcoholism, stuttering, and vestibular disorders. It also improves mental performance (attention, memory, speed and accuracy of sensory-motor reactions), physical performance, reduces sleep disorders as well as movement and speech disorders.
CNS Activity
Originator
Sources: Khaunma RA. Tranquillizing effects of beta-phenyl-gamma-aminobutyric acid (“Phenigama”). Byull Eksp Biol Med 1964;1:54–58
Curator's Comment: Phenibut (beta-phenyl-gamma-aminobutyric acid, beta-phenyl-GABA) was synthesized by Perekalin and his associates at the Department of Organic Chemistry of the Herzen Pe-dagogic Institute in St. Petersburg, Russia. https://www.ncbi.nlm.nih.gov/pubmed/11830761
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 177.0 µM [Ki] | |||
Target ID: CHEMBL3420 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PHENIBUT Approved UseAsthenic and Anxious-Neurotic States, Worry, Anxiety, Fear
Sleep Disorders
Tiredness
Improve Memory, Cognition, Mood |
|||
| Primary | PHENIBUT Approved UseAsthenic and Anxious-Neurotic States, Worry, Anxiety, Fear
Sleep Disorders
Tiredness
Improve Memory, Cognition, Mood |
|||
| Primary | PHENIBUT Approved UseAsthenic and Anxious-Neurotic States, Worry, Anxiety, Fear
Sleep Disorders
Tiredness
Improve Memory, Cognition, Mood |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Antiabstinent action of fenibut and baclofen on a model of abstinence induced by the benzodiazepine receptor antagonist CGS 8216 in rats receiving diazepam]. | 1987 Jun |
|
| [Experimental study of the antiepileptic activity of fenibut and its combinations with sodium valproate and aminooxyacetic acid]. | 1988 May-Jun |
|
| [Neurochemical characteristics of the ventromedial hypothalamus and anti-aversive effects of anxiolytic agents in various anxiety models]. | 2001 Sep |
|
| Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. | 2001 Winter |
|
| [Anti-arrhythmic properties of GABA and GABA-ergic system activators]. | 2002 Jan-Feb |
|
| [Cardiac effects of fenibut in development of experimental chronic renal insufficiency]. | 2003 Jul-Aug |
|
| Neurochemical characteristics of the ventromedial hypothalamus in mediating the antiaversive effects of anxiolytics in different models of anxiety. | 2003 Mar |
|
| [Peculiarities of nootropic effect of phenibut]. | 2006 |
|
| [Effect of phenibut on the respiratory arrest caused by serotonin]. | 2006 Jan-Feb |
|
| [Neurochemical features of the ventral pallidum in realization of the antiaversive effects of anxiolytics in different models of anxiety]. | 2006 Jan-Feb |
|
| Neurochemical mechanisms of the dorsal pallidum in the antiaversive effects of anxiolytics in various models of anxiety. | 2006 Sep |
|
| Quantitative analysis of phenibut in rat brain tissue extracts by liquid chromatography-tandem mass spectrometry. | 2008 Dec |
|
| [Effects of aminalon, fenibut, and picamilon on the typological parameters of cerebral hemodynamics in swimmers with dysadaptation syndrome]. | 2009 Jul-Aug |
|
| Comparative study of immunocorrective activity of phenibut and its organic salts in experimental immunodeficiency. | 2009 May |
|
| [Effects of phenibut on parameters of cerebral hemodynamics in swimmers with dysadaptation syndrome and various types of systemic hemodynamics]. | 2010 Aug |
|
| [Interhemisphere asymmetry of hippocampus and neocortex in correlates of active and passive behavioural strategy in negative emotional situations]. | 2010 Dec |
|
| [Comparative study of immunomodulating properties of phenibut and gammoxin]. | 2010 Dec |
|
| [Changes in the psycho-emotional state under conditions of suppressed immunogenesis, the correction of the disorders with GABA-positive means]. | 2010 Feb |
|
| Paired-pulse inhibition in the auditory cortex in Parkinson's disease and its dependence on clinical characteristics of the patients. | 2010 Nov 1 |
Patents
Sample Use Guides
Initial dose is 250-500 mg (1-2 pills) 3 times a day. Maximum single dose: 750 mg, for patients over 60 years: 500 mg. The course of treatment is 2-3 weeks. If necessary, the course of treatment can be prolonged to 4-6 weeks. Patients, who have somnolence or other central nervous system disturbances during administration of Phenibut, should be careful about driving.
Route of Administration:
Oral
It has been established in experiments on the isolated spinal cord of 7-14-day-old rats that the GABAB-mimetic phenibut (10-100 uM) elicits a slow-developing depolarization of motoneurons, suppression of spontaneous activity and polysynaptic reflex discharges of motoneurons, recorded from the ventral roots.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:51:13 GMT 2023
by
admin
on
Sat Dec 16 07:51:13 GMT 2023
|
| Record UNII |
625240H2LN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
18288
Created by
admin on Sat Dec 16 07:51:14 GMT 2023 , Edited by admin on Sat Dec 16 07:51:14 GMT 2023
|
PRIMARY | |||
|
m1730
Created by
admin on Sat Dec 16 07:51:14 GMT 2023 , Edited by admin on Sat Dec 16 07:51:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
300000017632
Created by
admin on Sat Dec 16 07:51:14 GMT 2023 , Edited by admin on Sat Dec 16 07:51:14 GMT 2023
|
PRIMARY | |||
|
625240H2LN
Created by
admin on Sat Dec 16 07:51:14 GMT 2023 , Edited by admin on Sat Dec 16 07:51:14 GMT 2023
|
PRIMARY | |||
|
3060-41-1
Created by
admin on Sat Dec 16 07:51:14 GMT 2023 , Edited by admin on Sat Dec 16 07:51:14 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
